Estimated FDA User Fee Review Goals For Pending NDAs/BLAs
This article was originally published in Pharmaceutical Approvals Monthly
Estimated user fee goals for FDA action on publicly disclosed NDAs, BLAs and efficacy supplements are calculated based on the date of receipt and assignment to standard or priority review. Resubmissions with significant new data or analyses have a 6-month goal. FDA may extend review goals.
You may also be interested in...
Round-up of the latest news across EMEA, including two deals for Bayer in Egypt and Saudi Arabia; Orkla's acquisition of NutraQ; and Uriach's deal for Sidroga.
Dutch firm TheOTCLab expands its home market presence with distribution rights to three international consumer health brands: Combe's feminine health brand Vagisil and male hair care range Just For Men and Foundation Consumer Brands’ Breathe Right Nasal Strips.
Cipla has expanded its partnership with Alvotech to cover the commercialization of five biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.